Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Combining Apremilast 30mg Bid With Narrowband UVB in the Treatment of Moderate-to-severe Plaque Psoriasis

NCT02412644 is registered in ClinicalTrials.gov with Psoriasis Treatment Center of Central New Jersey as lead sponsor.

NCT NCT02412644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02412644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Combining Apremilast 30mg Bid With Narrowband UVB in the Treatment of Moderate-to-severe Plaque Psoriasis
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Phase
Phase 4
Overall status
Completed
Start date
May 28, 2015
Completion date
July 31, 2016
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis